By Mill Chart
Last update: Jul 11, 2024
TG THERAPEUTICS INC (NASDAQ:TGTX) has caught the eye of our stock screener as an affordable growth stock. NASDAQ:TGTX is displaying robust growth metrics and also excels in terms of profitability, solvency, and liquidity. Additionally, it appears to be reasonably priced. Let's delve into the details.
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:TGTX has earned a 8 for growth:
To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:TGTX has achieved a 5 out of 10:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:TGTX has earned a 6 out of 10:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:TGTX has earned a 5 out of 10:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
Check the latest full fundamental report of TGTX for a complete fundamental analysis.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
37.085
-0.59 (-1.55%)
Find more stocks in the Stock Screener
TG Therapeutics (TGTX) meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including 1,300% EPS growth and 90% revenue expansion. A breakout above $37.27 could signal further upside.
TG Therapeutics (TGTX) shows strong earnings momentum with 142% EPS growth and a bullish technical setup, making it a candidate for high-growth investors.